ArticleInternational journal of clinical and experimental pathology2017
Estrogen receptor β inhibits prostate cancer cell proliferation through downregulating TGF-β1/IGF-1 signaling.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Small molecule conjugates with selective estrogen receptorActa pharmaceutica Sinica. B · 2024Article
- Review
- Signal Crosstalk and the Role of Estrogen Receptor beta (ERβ) in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, estrogen receptor β (ERβ) appears to be anti-proliferative and pro-apoptotic in normal prostate gland, but its role in androgen independent prostate cancer is limited. In this study, the expression of ERβ was overexpressed in two androgen-independent prostate cancer cell lines, PC-3 and DU145 after transfection with Ad-ERβ-EGFP virus particles. Overexpressed ERβ significantly inhibited cell proliferation in these two prostate cancer cell lines using MTT assay. Flow cytometry and Annexin V-APC/7-AAD double staining confirmed that upregulation of ERβ increased cell apoptotic rate. We found that upregulation of ERβ suppressed the expression of TGF-β1/IGF-1 expression, which could be reversed by ERβ-selective antagonist PHTPP. Consistently, TGF-β1 inhibitor LY2109761 treatment could weaken the effects of ERβ-selective antagonist PHTPP on the expression of IGF-1, survivin and bcl-2 in prostate cancer cells. In conclusion, these results suggest that estrogen may play an important role in androgen-independent prostate cancer cell proliferation through ERβ-mediated suppression of TGF-β1/IGF-1.
Indexed as
Identifiers
31966711PMC6965446W3027002441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.